ELIQUIS
PeakNDAORALTABLET, FOR SUSPENSIONPriority Review
Approved
Dec 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10
Data completeness
7/8 — Comprehensive
Priority Review
ELIQUIS by Bristol Myers Squibb is fxa. Approved for deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe), knee replacement surgery and 7 more indications. First approved in 2012.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELIQUIS (apixaban) is an oral anticoagulant that selectively inhibits Factor Xa, preventing thrombin generation and clot formation without requiring antithrombin III as a cofactor. It is indicated for stroke prevention in atrial fibrillation and treatment of venous thromboembolism. The drug works by inhibiting both free and clot-bound Factor Xa, indirectly reducing platelet aggregation induced by thrombin.
$18.3BPart D
PeakStable
5.3 years to LOEELIQUIS dominates the anticoagulant market at peak lifecycle with 21+ million annual claims, supporting large brand teams and stable commercial operations.
Mechanism of Action
FXa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban…
Worked on ELIQUIS at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.